Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.49 USD
Change Today -0.03 / -0.85%
Volume 529.1K
THLD On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

threshold pharmaceuticals (THLD) Snapshot

Open
$3.54
Previous Close
$3.52
Day High
$3.67
Day Low
$3.48
52 Week High
09/9/14 - $5.41
52 Week Low
11/7/14 - $2.58
Market Cap
249.0M
Average Volume 10 Days
602.4K
EPS TTM
$-0.40
Shares Outstanding
71.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THRESHOLD PHARMACEUTICALS (THLD)

threshold pharmaceuticals (THLD) Related Businessweek News

No Related Businessweek News Found

threshold pharmaceuticals (THLD) Details

Threshold Pharmaceuticals, Inc., a biotechnology company, discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the United States. Its lead investigational small molecule is evofosfamide, which is in two Phase III clinical trials for the treatment of soft tissue sarcoma indication and pancreatic cancer; Phase II clinical trials for treating non-squamous non-small cell lung cancer; Phase II clinical trials for advanced melanoma and soft tissue sarcoma; Phase I/II clinical trials for multiple myeloma and pancreatic cancer; and Phase I clinical trials for the treatment of solid tumors, pancreatic cancer, and advanced solid tumors. The company is also involved in the study of evofosfamide in investigator sponsored trials, including Phase I/II clinical trials for glioblastoma; Phase II clinical trials for glioblastoma and pancreatic neuroendocrine tumors; and Phase I clinical trials for advanced kidney cancer or liver cancer. In addition, it engages in developing antiangiogenic therapies in various tumor types in human clinical trials; TH-4000, an investigational hypoxia-activated EGFR tyrosine kinase inhibitor; and [18F]-HX4, an investigational PET imaging agent for hypoxia. The company has a license and co-development agreement with Merck KGaA to co-develop and commercialize evofosfamide; license agreement with Auckland UniServices Ltd. for the development program based on TH-4000; and license agreement with Eleison Pharmaceuticals, Inc. for the manufacture, development, and commercialization of glufosfamide for the treatment of cancer in humans and animals, as well as other uses. Threshold Pharmaceuticals, Inc. was founded in 2001 and is headquartered in South San Francisco, California.

62 Employees
Last Reported Date: 04/30/15
Founded in 2001

threshold pharmaceuticals (THLD) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $575.0K
Vice President of Finance and Controller
Total Annual Compensation: $273.0K
Chief Medical Officer
Total Annual Compensation: $395.0K
Senior Vice President of Regulatory Affairs &...
Total Annual Compensation: $320.0K
Senior Vice President of Pharmaceutical Devel...
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2014.

threshold pharmaceuticals (THLD) Key Developments

Threshold Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Threshold Pharmaceuticals Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. Revenue for the first quarter ended March 31, 2015 was $3.681 million compared to $3.681 million a year ago. Loss from operations was $9.615 million compared to $8.606 million a year ago. The net loss for the first quarter of 2015 was $11.2 million or $0.17 per diluted share compared to a net loss of $7.1 million or $0.14 per diluted share for the first quarter of 2014.

Threshold Pharmaceuticals Inc. - Analyst/Investor Day

To discuss its clinical development programs for evofosfamide (formerly TH-302) and TH-4000

Threshold Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Clinical Outlook Related to the Development of Evofosfamide

Threshold Pharmaceuticals Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported revenue of $3,681,000 against $3,212,000 a year ago. Loss from operations was $7,551,000 against $7,774,000 a year ago. Loss before provision for taxes was $5,964,000 against $7,508,000 a year ago. Net loss was $5,964,000 or $0.12 per diluted share against $7,589,000 or $0.13 per diluted share a year ago. For the year, the company reported revenue of $14,722,000 against $12,495,000 a year ago. Loss from operations was $31,251,000 against $26,024,000 a year ago. Loss before provision for taxes was $21,584,000 against $28,213,000 a year ago. Net loss was $21,584,000 or $0.49 per diluted share against $28,415,000 or $0.49 per diluted share a year ago. The development plan for evofosfamide is designed to investigate its safety and efficacy across a broad range of solid tumors and hematologic malignancies. Evofosfamide is being developed in therapeutic areas supported by preclinical and clinical data and where there is high unmet need for new anti-cancer agents. To date, evofosfamide has been evaluated in more than 1,500 patients with cancer. Threshold anticipates the following development activities related to company- and Merck KGaA, Darmstadt, Germany-sponsored clinical trials for evofosfamide in 2015: Continue to efficiently execute the two Phase 3 clinical trials of evofosfamide to allow for timely data analyses and to prepare for the potential submission of marketing applications, assuming the data from the trials are supportive; Continue to enroll the Phase 2 clinical trial of evofosfamide designed to support registration for the treatment of patients with non-squamous non-small cell lung cancer; Complete enrollment in the Phase 2 clinical trial of evofosfamide in combination with bortezomib (Velcade) and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma; and Continue to enroll patients in the company's Phase 2 biomarker trial in patients with advanced melanoma.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THLD:US $3.49 USD -0.03

THLD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for THLD.
View Industry Companies
 

Industry Analysis

THLD

Industry Average

Valuation THLD Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THRESHOLD PHARMACEUTICALS, please visit www.thresholdpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.